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management of dyslipidaemia 
Evidence and practical recommendations
the management of dyslipidaemia is a key aspect of 
managing cardiovascular risk. While this article focuses on 
lipid management, many patients have multiple risk factors 
that also require appropriate treatment. Dyslipidaemia should 
not be treated in isolation from other risk factors.
 
Treating to lipid targets is a worthwhile goal that can be challenging 
to achieve (Table 1). Not all patients who require lipid lowering 
therapy achieve target levels in clinical practice. However, there is a 
well recognised continuous linear relationship between cholesterol 
levels and cardiovascular events.
absolute risk
Recommendations for managing cardiovascular risk previously focused 
on individual risk factors. Today, however, there is an international 
trend to use absolute risk to best identify who should receive medical 
intervention and to what extent.1 Absolute risk is the probability, 
expressed as a percentage, that an individual will have an adverse 
cardiovascular event over a specified time period, usually 5 or 10 years. 
 The absolute risk approach should be used to determine those 
individuals in the general population with the highest risk of future 
vascular events. Those with overt cardiovascular disease (CVD) 
(coronary heart disease, stroke, peripheral artery disease) do not 
require formal assessment as they are already at very high risk of 
subsequent events and require aggressive treatment.
 The use of 5 year absolute risk of cardiovascular events is 
generally recommended (Table 2). There are several Framingham 
study data based computer and paper tools available for calculating 
absolute risk.2,3
 Some patients already have a higher absolute risk for CVD than 
is suggested by the use of a risk calculator. In these high risk groups, 
treatment can be initiated immediately; calculation of absolute risk is 
not required before intervention. These groups include patients with 
very high individual risk factors (eg. familial hypercholesterolaemia, 
severe hypertension) or target organ damage (eg. left ventricular 
hypertrophy or proteinuria).
Background
Dyslipidaemia is a common condition managed in general practice.
Objective
This article reviews the evidence and gives practical advice for the 
management of dyslipidaemia in general practice.
Discussion
It is essential to identify people at risk of cardiovascular disease 
(CVD) and to instigate appropriate treatment strategies. An 
assessment of absolute risk is the most appropriate method of 
identifying those at a higher risk of CVD where CVD is not overt. 
People with an absolute risk of >15% of a cardiovascular event in 
the next 5 years should be actively treated. Drug therapy should 
also be considered in those estimated to be at 10–15% risk of a 
cardiovascular event in the next 5 years if they have additional risk 
factors. It is important to select an appropriate lipid lowering therapy 
(or combination of drugs) in order to reach lipid targets, which need 
to consider not just LDL-c but also HDL-c and triglycerides. Lifestyle 
management should underpin all lipid management strategies.
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options. A large body of clinical trial data has shown that achieving 
lower levels of LDL-c translates to increased therapeutic benefit, 
particularly when lowered to <2.0 mmol/L in high risk patients.8–10
 National Heart Foundation treatment guidelines suggest a 
modest increase in the level of HDL-c is also beneficial.5 While 
raising HDL-c is desirable, it is sometimes difficult as at least 50% 
of the variability in HDL-c concentration is determined genetically. 
One major secondary intervention trial with a fibrate in subjects 
with metabolic syndrome type dyslipidaemia showed reductions in 
cardiovascular endpoints that related to improved HDL-c levels.11
 There is also good evidence that a high triglyceride (TG) level 
(>2 mmol/L) is associated with higher cardiovascular risk and 
should be treated, especially in the presence of low HDL-c, and 
when indicated in patients with combined hyperlipoproteinaemia in 
whom LDL-c is also raised.5 However, there is currently insufficient 
evidence to conclude that reducing TG with drugs is valuable 
in patients with normal LDL-c and HDL-c and no evidence of 
metabolic syndrome.
management strategies based on absolute risk
lifestyle
Management of all patients – including those at high risk – should 
be underpinned by lifestyle modification (Table 3).5 Lifestyle changes 
can also improve the efficacy of medication in treating to target. The 
actual management of risk factors will depend on which ones are 
present. Lifestyle management is likely to require ongoing support 
from general practitioners to be sustainable.5 
Drug therapy
A large body of evidence supports the use of lipid modifying therapy 
for reducing the risk of CVD, primarily via a reduction in LDL-c 
(Table 4).5 The most convincing data is for statins and these agents 
should generally be used first line for cardiovascular protection. 
Specific lipid abnormalities, such as hypertriglyceridaemia, may 
require different lipid lowering agents.
 Lipid modifying therapy is indicated for those individuals who 
have a >15% absolute risk of a cardiovascular event in the next 5 
years.5 Drug therapy should also be considered in those estimated 
to be at 10–15% risk of a cardiovascular event in the next 5 years 
if they have additional risk factors. (PBS criteria for eligibility 
for subsidy should be taken into account, particularly for those 
assessed to be in the lower risk group described above.)
 General practitioners are advised to select therapy that will 
deliver an effective reduction in LDL-c at the approved starting 
dose and to titrate as required. Dose titration and/or a change 
in medication may be required to reach target lipid levels. 
Additional treatment will be required if LDL-c targets are not met 
at the maximal tolerated dose of statin, or if HDL-c is low or TG is 
high,  despite the LDL-c being at  target.  L i festyle and 
adherence should also be reassessed before deciding to add 
additional medications.
 Framingham based CVD risk assessment is also unsuitable 
for other high risk population groups – including Aboriginal 
people, Torres Strait Islanders and Pacific Islanders – because the 
actual risk of CVD is substantially underestimated, particularly 
in young adults and women.4 If these groups have an LDL-c >2.5 
mmol/L after lifestyle intervention they should be considered 
for statin therapy, even without pre-existing vascular disease or 
diabetes.5 Risk estimation for those over 70 years of age is also 
problematic as no individuals over 70 years of age were included 
in the original Framingham cohort. These tools also underestimate 
individuals with very high isolated risk factors. For example, familial 
hypercholesterolaemia has specific drug therapy recommendations: 
statins initially for men >18 years and women >30 years of age 
unless pregnancy is anticipated soon.6 Statin therapy for severe 
hypercholesterolaemia has been advocated as safe even for children 
(>8–10 years of age).6
central obesity and the metabolic syndrome
The metabolic syndrome is a cluster of risk factors that confers 
an increased risk of CVD. The components include hypertension, 
dyslipidaemia and glucose intolerance. Central (visceral) obesity 
is a prerequisite for diagnosis and is assessed using waist 
circumference.7
treating to new and more aggressive targets
It is often challenging to reach lipid targets in clinical practice. The 
higher the baseline LDL-c, the harder it is to reach the treatment 
target. However, the advent of more potent therapies at well 
tolerated doses provides prescribers with good therapeutic 
Table 1. Recommended lipid targets in patients with CHD5
More emphasis on LDL-c rather than total cholesterol
•	 LDL-c		 	 <2.0	mmol/L
•	 HDL-c		 	 >1.0	mmol/L
•	 Triglycerides		 <1.5	mmol/L
Table 2. Identifying high risk individuals for medical intervention5
•	 Those	with	overt	CVD
•	 	Those	with	a	calculated	absolute	risk	of	≥15%	of	a	CVD	
event in the next 5 years 
•	 	People	with	a	calculated	absolute	risk	of	10–15%	of	a	
CVD event in the next 5 years when other risk factors are 
present such as: 
 –  family history of premature CHD (first degree relative 
who developed CHD before age 60 years) 
 – metabolic syndrome
 – obesity
 – chronic kidney disease
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statin therapy for 18–24 months was associated with regression 
of coronary atherosclerosis (assessed via serial intravascular 
ultrasound) when LDL-c was substantially reduced and HDL-c was 
increased by more than 7.5%.13 The researchers suggest that statin 
benefits are derived from both reductions in atherogenic lipoprotein 
levels and increases in HDL-c.
 While all statins have a modest effect on HDL-c, rosuvastatin 
appears to be the most potent of its class in terms of raising HDL-c.14 
It is important to note that the magnitude of change in HDL-c may 
be overshadowed by laboratory variability and clinicians should 
consider this when assessing response to treatment.
 Drug and lifestyle regimens that achieve the greatest reduction 
in LDL-c, coupled with a modest yet significant increase in HDL-c, 
will confer significant benefit to the majority of patients requiring 
treatment for dyslipidaemia in general practice.
relationship between hDl-c and lDl-c
There is currently no solid evidence to suggest that high HDL-c 
will neutralise high levels of LDL-c. In some people, the function 
of HDL-c is inadequate and thus high levels may not confer 
 Once at target, all patients at high, risk should have their lipid 
levels re-measured – ideally every 6 months, but no less than every 
12 months – as part of the ongoing assessment of adherence and 
management of overall cardiovascular risk (Figure 1). 
secondary prevention
Patients who have CVD are considered at very high absolute risk 
and should be treated aggressively to reach target lipid levels. 
Diagnosis of diabetes implies high absolute risk, especially when 
patients have other CVD risk factors.5 In general practice it is 
particularly important to prevent patients with overt CVD from 
drifting away from evidence based therapies. It is also important 
to recognise CVD incidents. Be particularly vigilant in those with 
diabetes (‘silent’ AMIs) or those at high risk for peripheral arterial 
disease. The latter are likely to have generalised vascular disease 
and are at higher risk of CVD morbidity and mortality than those 
with overt coronary artery disease or cerebrovascular disease.12
 Statins have been shown to be beneficial in all patients with 
vascular changes regardless of baseline LDL-c level. This applies to 
older and younger age groups and to those with diabetes.5,9
importance of hDl-c
Low HDL-c is a recognised coronary heart diseae risk factor, and a 
moderate rise in HDL-c is desirable (Table 5). Many people with low 
HDL-c have metabolic syndrome, so it is important to manage all 
risk factors appropriately.
 Raising HDL-c to >1.0 mmol/L has probable therapeutic benefits, 
although pivotal intervention trials have not yet demonstrated 
whether improvements in HDL-c translate to meaningful reductions 
in clinical events and improved clinical outcomes. A recent post-hoc 
analysis of data from four prospective randomised trials, involving 
1455 subjects with angiographic coronary disease, showed that 
Table 3. Lifestyle interventions
•	 	It	is	most	appropriate	to	start	with	smoking	cessation	in	
those who smoke. Brief advice from a GP is a cost effective 
strategy for assisting patients to quit smoking12
•	 	Nutrition	–	referral	to	a	dietician	should	be	considered	or	
discuss cholesterol lowering diet. Complementary options 
to reduce cholesterol include plant sterols, psyllium, and 
policosanol 
•	 	Moderate	alcohol	intake	has	been	associated	with	raised	
HDL-c and may confer some degree of cardioprotection.17 
However, this evidence is from observational studies and 
therefore is not recommended as an intervention
•	 	Physical	activity	and	weight	loss	are	particularly	effective	
in people with metabolic syndrome where low HDL-c is part 
of a dyslipidaemic pattern. The degree of improvement in 
HDL-c is proportional to the quantum of vigorous exercise.18 
Referral to a dietician and/or exercise physiologist is 
recommended
Table 4. Lipid lowering agents 
•	 	Statins	–	considered	the	agents	of	choice	for	reducing	
the level of LDL-c, and have modest HDL-c-raising and 
triglyceride lowering effects. Recommended for all patients 
with clinical evidence of vascular disease (coronary heart 
disease, stroke, peripheral artery disease) regardless of 
LDL-c level; should be commenced in hospital for those 
admitted with incident CHD events5
•	 	Fibrates	–	patients	with	type	2	diabetes	or	the	metabolic	
syndrome with elevated triglycerides and/or low HDL-c may 
benefit from fibrate therapy alone, or in combination with 
a statin, especially when LDL-c is also raised. The effect 
of fenofibrate on HDL-c may be gradual and extend over 6 
months. Gemfibrozil interacts with statins and should not 
be used in combination5
•	 	Ezetimibe	–	member	of	a	new	class	of	drugs	that	inhibit	the	
absorption of cholesterol by the intestine; has a synergistic 
effect when combined with statins; shown to reduce 
the concentration of LDL-c by 15–20% when given as 
monotherapy and up to 25% when added to a statin5
•	 	Nicotinic	acid	–	an	effective	drug	in	raising	HDL-c	and	
lowering triglycerides while also reducing LDL-c. However 
it is associated with flushing despite prophylactic aspirin, 
which inhibits its use in most patients. Newer forms, with 
reduced flushing effects, are under development19, 20
•	 	Fish	oils	–	contain	highly	polyunsaturated	long	chain	
n-3 fatty acids which can lower TG concentrations. A 50% 
reduction in TG concentrations has been shown with a daily 
intake of 2–5 g of n-3 fatty acids (equivalent to 6–15 g of 
fish oil). Small and variable changes in LDL-c and HDL-c 
levels have also been demonstrated21
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Figure 1. Management of dyslipidaemia: a population based approach in people with no evidence of vascular disease
•  The starting dose of statin therapy depends on baseline cholesterol.  
Start with the dose most likely to achieve LDL-c reductions and treatment 
targets with minimal side effects. Consult relevant prescribing information for 
specific details and refer to PBS criteria
measure fasting cholesterol every 5 years in adults aged >45 years (primary prevention)
Assess other cardiovascular risk factors
If dyslipidaemia:
•	remeasure,	including	full	lipid	profile
•	assess	absolute	risk
•	provide	lifestyle	intervention	(smoking	cessation,	dietary	changes,	increased	physical	activity)
Targets reached:
•	review	6–12	months
Review 4–6 weeks
Targets not reached:
•		step	titrate	statin	dose	or	switch	to	
another statin. Consider adding a 
second or third agent
Re-assess 6–8 weeks
Review 4–6 weeks
•	Review	4–6	weeks
•		Assess	presence	of	side	effects	(LFTs,	CK	if	myalgia);	
re-assess and reinforce lifestyle changes
If all lipid values at target or above target 
and low/moderate absolute risk:
•	re-assess	(ideally	3–6	months)
If at/near target LDL-c but TG and HDL-c 
remain abnormal and absolute risk is high:
•	consider	adding	fibrate	and	fish	oil
Targets reached:
•		review	3	months	then	 
every 6 months thereafter
Targets not reached:
•	review	lifestyle,	adherence
•	titrate	statin	dose
•		consider	fibrate	if	TG,	HDL-c	remain	abnormal
If not at target and absolute risk is high: 
•		commence	statin*	(discuss	side	effects,	targets,		
evidence for prevention of events)
•	measure	pre-treatment	LFTs
•	re-assess	and	reinforce	lifestyle	changes
cardioprotection. This is particularly true in people with existing 
vascular disease where a high HDL-c level should not be assumed 
to be cardioprotective.15 Thus, while it is desirable to have 
raised HDL-c, it should not detract from treating high LDL-c 
levels to target. Patients with existing CVD need appropriate 
and aggressive treatment irrespective of HDL-c levels. Increasing 
physical activity and reducing weight (in overweight individuals) 
may increase HDL-c.16
laboratory testing 
The decision to initiate drug treatment should not be made on the 
basis of a single measurement. It is important to ask specifically for 
HDL-c to be measured, as it is not a routine part of lipid testing.
safety 
In general, current lipid modifying treatments are well tolerated with 
a good safety profile. Liver function tests (LFTs) should be undertaken 
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LDL-c lowering or the patient is intolerant to statins. The currently 
available form of nicotinic acid is poorly tolerated and best 
prescribed by specialist clinics.
 Patients need to understand why they need long term medication 
for a condition with no symptoms. Because there are no symptoms, 
the presence of side effects is a major reason for nonadherence. 
Education should equate management of ‘good and bad cholesterol’ 
for prevention of cardiovascular events. Adherence is the key to 
success (Table 6).
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•	 	Emphasise	that	this	is	lifelong	therapy	for	most	(unless	
there are profound and sustained lifestyle changes in those 
without overt CVD or in those with residual high absolute 
risk, which may warrant a trial off medication)
•	 	Let	patients	know	that	the	longer	they	stay	on	therapy,	the	
greater the likely benefit
•	 	Establish	and	share	clear	goals	of	treatment	and	target	
levels
•	 	Provide	feedback	about	changes	in	lipid	levels,	blood	
pressure, absolute risk, waist circumference
•	 Emphasise	diet	and	lifestyle	modification	throughout
•	 Provide	resources
•	 Appreciate	the	cost	to	the	patient	of	multiple	treatments
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poorly controlled diabetes often have raised TG that 
responds to optimising glucose metabolism
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